Role of GLP-1R in T Cells and Its Regulatory Mechanism for Anti-transplant Immunity and Anti-tumor Immunity Academic Background Glucagon-like peptide-1 receptor (GLP-1R) is known as a key regulator of glucose metabolism, primarily expressed in pancreatic β cells. Previous studies have clarified that GLP-1R agonists have significant effects in reduc...

Application of Base Editing Screening Technology in Tumor Immunotherapy T Cell Research Immune cell therapies, such as T cell transfer therapy and CAR T cell therapy, have become important clinical cancer treatment tools in certain disease fields. However, most cancer patients fail to benefit from cell therapies, possibly due to inherent changes in...

Immunoglobulin Superfamily Ligand B7H6 Enables T Cell Responses under NK Cell Surveillance Background In the field of immunology, understanding the mechanisms regulating T cell immunity is crucial for developing effective therapies for diseases related to T cell dysfunction, such as autoimmune diseases, chronic infections, and cancer. T cells media...

Single-Cell Topographical Analysis Reveals Biomechanical Characteristics of Cytotoxic T Cells Introduction In recent years, research on how the immune system functions in different mechanochemical environments has shown that immune cells dynamically alter their shape and exert forces on their surroundings to sense physical parameters and activate i...

Targeting T Cell Plasticity to Treat Inflammation in the Kidney and Gut: A Study Using Pooled Single-cell CRISPR Screening Background of the Study This paper, co-authored by Leon U.B. Enk and others, was published in the June 14, 2024, issue of “Science Immunology” under the title “Targeting T cell plasticity in kidney and gut inflammation by poole...

Nucleotide Adduct Binding MR1 and Activation of MR1-Restricted T Cells Academic Background MR1T cells, a recently discovered class of T cells, can recognize antigens presented by MHC class I-related molecule MR1 without microbial infection. These cells exhibit both helper and cytotoxic properties in vitro, but the endogenous antigens they recognize...

Tracking In Situ Checkpoint Inhibitor-Bound Target T Cells Academic Background Checkpoint inhibitors (CPIs) have revolutionized cancer treatment by blocking immune regulatory signals mediated by checkpoint molecules, restoring T cell-mediated tumor clearance. However, these therapies also lead to a range of immune-related adverse events (IRAEs), wi...